Good dose for Viralytics

By Dylan Bushell-Embling
Wednesday, 20 August, 2008

Viralytics [ASX: VLA] has completed dosage administration of the second of three groups of patients in its phase 1 trial of its oncolytic virus technology Cavatak in late-stage metastatic melanoma patients.

After dosing the two groups the company has concluded that there were no adverse effects related to the medication, and that the two tested doses were well tolerated.

The company has also received ethics approval from the Drug Safety Monitoring Committee [DSMC] to provide an escalated dose to the final group of patients.

The final participants will include a tenfold higher dose than the second group, and a hundredfold higher dose than the first group.

Viralytics also has a second trial underway in prostate cancer patients.

Related News

'Mini brains' mimic MS myelin damage

The MS organoids give researchers a highly detailed cellular view of myelin destruction...

Fast-aging placentas may contribute to pre-eclampsia

Placentas affected by pre-eclampsia show several signs of accelerated aging, including increased...

BioNTech opens mRNA manufacturing facility at La Trobe

Offering state-subsidised access to researchers and biotech startups, the facility aims to enable...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd